An overview of anthrax infection including the recently identified form of disease in injection drug users
- 24 April 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Intensive Care Medicine
- Vol. 38 (7), 1092-1104
- https://doi.org/10.1007/s00134-012-2541-0
Abstract
Purpose Bacillus anthracis infection (anthrax) can be highly lethal. Two recent outbreaks related to contaminated mail in the USA and heroin in the UK and Europe and its potential as a bioterrorist weapon have greatly increased concerns over anthrax in the developed world. Methods This review summarizes the microbiology, pathogenesis, diagnosis, and management of anthrax. Results and conclusions Anthrax, a gram-positive bacterium, has typically been associated with three forms of infection: cutaneous, gastrointestinal, and inhalational. However, the anthrax outbreak among injection drug users has emphasized the importance of what is now considered a fourth disease form (i.e., injectional anthrax) that is characterized by severe soft tissue infection. While cutaneous anthrax is most common, its early stages are distinct and prompt appropriate treatment commonly produces a good outcome. However, early symptoms with the other three disease forms can be nonspecific and mistaken for less lethal conditions. As a result, patients with gastrointestinal, inhalational, or injectional anthrax may have advanced infection at presentation that can be highly lethal. Once anthrax is suspected, the diagnosis can usually be made with gram stain and culture from blood or tissue followed by confirmatory testing (e.g., PCR). While antibiotics are the mainstay of anthrax treatment, use of adjunctive therapies such as anthrax toxin antagonists are a consideration. Prompt surgical therapy appears to be important for successful management of injectional anthrax.Keywords
This publication has 85 references indexed in Scilit:
- Protective Antigen Antibody Augments Hemodynamic Support in Anthrax Lethal Toxin Shock in CaninesThe Journal of Infectious Diseases, 2012
- Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart modelAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Anthrax Lethal and Edema Toxins Produce Different Patterns of Cardiovascular and Renal Dysfunction and Synergistically Decrease Survival in CaninesThe Journal of Infectious Diseases, 2010
- Novel Chimpanzee/Human Monoclonal Antibodies That Neutralize Anthrax Lethal Factor, and Evidence for Possible Synergy with Anti-Protective Antigen AntibodyInfection and Immunity, 2009
- Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor bindingProceedings of the National Academy of Sciences, 2009
- Cellular and systemic effects of anthrax lethal toxin and edema toxinMolecular Aspects of Medicine, 2009
- Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats*Critical Care Medicine, 2009
- Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect againstBacillus anthracisInfection and Enhance Endogenous Immunity to AnthraxInfection and Immunity, 2007
- Prophylaxis and Therapy of Inhalational Anthrax by a Novel Monoclonal Antibody to Protective Antigen That Mimics Vaccine-Induced ImmunityInfection and Immunity, 2006
- Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthraxProceedings of the National Academy of Sciences of the United States of America, 2006